News | December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Hansoh Pharma will receive an upfront payment in the low double-digit millions
India plays a critical role in Bristol Myers Squibb’s global strategy
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The FDA aims to make a decision by April 8, 2026
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
